🎤 Upcoming Biotech Conferences
Obesity & Metabolic Biotech Pipeline: Weight Loss and Diabetes Drugs
Every obesity and metabolic disease program BioRadar tracks across 95 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 386 obesity and metabolic disease drug programs across 95 public companies. The most active companies by program count are MNKD, ORMP, LLY, LXRX, NVO.
Companies with obesity and metabolic disease programs
Phase 3 obesity & metabolic programs (114)
| Ticker | Drug | Indication |
|---|---|---|
| ABEO | MSI-78 | Diabetic Foot Ulcers |
| ABEO | ofloxacin | Diabetic Foot Ulcers |
| ABT | Sotagliflozin Low Dose | Type 1 Diabetes (T1D) |
| ABT | Sotagliflozin High Dose | Type 1 Diabetes (T1D) |
| ALKS | Human Insulin Inhalation Powder | Diabetes Mellitus |
| ALKS | injected insulin | Diabetes Mellitus |
| ALKS | Injectable insulin | Diabetes Mellitus, Type 2 |
| ALKS | Insulin Glargine | Diabetes Mellitus, Type 2 |
| ALT | Pemvidutide | Metabolic Dysfunction-Associated Steatohepatitis ( |
| ALVO | AVT29 (proposed aflibercept HD biosimila | Diabetic Macular Edema |
| ALVO | Eylea HD (aflibercept HD) | Diabetic Macular Edema |
| AMGN | Semaglutide | Diabetes Mellitus, Type 2 |
| ARWR | zodasiran Injection | Homozygous Familial Hypercholesterolemia |
| ARWR | Zodasiran | Homozygous Familial Hypercholesterolemia |
| AZN | AZD0780 | Dyslipidaemia |
| AZN | Rosuvastatin Dose 1 | Dyslipidaemia |
| AZN | Rosuvastatin dose 2 | Dyslipidaemia |
| COLL | Empagliflozin 20 mg | Metabolic Syndrome |
| COLL | Empagliflozin 10 mg | Metabolic Syndrome |
| EOCN | Aramchol free acid | Nonalcoholic Steatohepatitis (NASH) |
| FDMT | EYELEA ® (aflibercept) Injection 2 mg (0 | Diabetic Macular Edema (DME) |
| FDMT | 4D-150 IVT (3x10^10 vg) | Diabetic Macular Edema (DME) |
| GPCR | Aleniglipron | Obesity |
| IVA | IVA337 | NASH - Nonalcoholic Steatohepatitis |
| KLRA | Ribupatide | Obesity With Diabetes |
| KLRA | Semaglutide | Obesity |
| KOD | Tabirafusp tedromer | Diabetic Macular Edema (DME) |
| KOD | Aflibercept (2.0 mg) | Diabetic Macular Edema (DME) |
| KOD | Tarcocimab | Diabetic Retinopathy |
| KOD | KSI-301 | Non-proliferative Diabetic Retinopathy |
| LLY | Retatrutide | Obesity |
| LLY | Eloralintide | Obesity |
| LLY | eloralintide and tirzepatide | Obesity |
| LXRX | Sotagliflozin | Diabetic Nephropathies |
| LXRX | Sotagliflozin Low Dose | Type 1 Diabetes (T1D) |
| LXRX | Sotagliflozin High Dose | Type 1 Diabetes (T1D) |
| LXRX | Sotagliflozin (SAR439954) | Type 2 Diabetes Mellitus |
| LXRX | Metformin | Type 2 Diabetes Mellitus |
| LXRX | Sulfonylurea | Type 2 Diabetes Mellitus |
| LXRX | Oral Antidiabetes Drugs (OADs) | Type 2 Diabetes Mellitus |
Phase 2 obesity & metabolic programs (168)
| Ticker | Drug | Indication |
|---|---|---|
| ABBV | Standard of Care | Diabetic Retinopathy, DR |
| ABBV | Aflibercept | Diabetic Retinopathy, DR |
| AKBA | IW-1973 | Type 2 Diabetes Mellitus With Diabetic Nephropathy |
| ALGS | ALG-055009 | NASH |
| ALNY | ALN-2232 | Obesity |
| ALNY | Tirzepatide | Obesity |
| ALNY | ALN-4324 | Type 2 Diabetes Mellitus (T2DM) |
| ALNY | ALN-KHK | Type 2 Diabetes Mellitus (T2DM) |
| ALT | ALT-801 | Obesity/Overweight |
| APMD | AD981 | Obesity Hypoventilation Syndrome (OHS) |
| ARWR | ARO-ANG 3 Injection | Homozygous Familial Hypercholesterolemia |
| ARWR | ARO-APOC3 | Dyslipidemias |
| ARWR | ARO-ANG3 | Mixed Dyslipidemia |
| ARWR | ARO-DIMERPA | Hyperlipidemia; Mixed |
| ARWR | ARO-ALK7 | Obesity |
| ARWR | Tirzepatide | Obesity |
| ARWR | ARO-INHBE | Obesity |
| BIOA | Oral BGE-102 | Obesity and Cardiovascular Risk |
| BIOA | Anti-VEGF | Diabetic Macular Edema (DME) |
| BIOA | Oral Azelaprag (BGE-105) | Obesity |
| BIOA | Tirzepatide | Obesity |
| BMEA | BMF-219 | Type 2 Diabetes Mellitus |
| BMEA | icovamenib 100mg | Type 2 Diabetes |
| BMEA | icovamenib 100 mg | Type 2 Diabetes |
| CELZ | CELZ-201 Administration | Type 1 Diabetes |
| CELZ | C-peptide | Diabetes Mellitus, Type 1 |
| CORT | Miricorilant | Antipsychotic-induced Weight Gain (AIWG) |
| CORT | Miricorilant (Cohort A) | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant (Cohort B) | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorlilant | Antipsychotic-induced Weight Gain (AIWG) |
| CPIX | Atorvastatin injection | Hypercholesterolemia |
| EDIT | Drug: EDIT-401 | Heterozygous Familial Hypercholesterolemia (HeFH) |
| ELDN | Islet transplantation with Tegoprubart ( | Type 1 Diabetes Mellitus |
| ELDN | Isolated cadaveric islet cells | Brittle Type 1 Diabetes Mellitus |
| ELDN | AT-1501 IV Infusion | Brittle Type 1 Diabetes Mellitus |
| FBLG | SoC + High dose CYWC628 | Diabetic Foot Ulcer (DFU) |
| FBLG | SoC + Low dose CYWC628 | Diabetic Foot Ulcer (DFU) |
| GPCR | ACCG-2671 | Obesity |
| GPCR | GSBR-1290 | Overweight or Obesity |
| GRFS | IGIV-C | Diabetes Complications |
Phase 1 obesity & metabolic programs (67)
| Ticker | Drug | Indication |
|---|---|---|
| ABUS | PRO-040201 | Hypercholesterolemia |
| ALNY | ALN-6222 | Obesity |
| ALT | Warfarin | NASH - Nonalcoholic Steatohepatitis |
| ALT | Atorvastatin | NASH - Nonalcoholic Steatohepatitis |
| ALT | Ethinylestradiol and Levonorgestrel | NASH - Nonalcoholic Steatohepatitis |
| ALT | Digoxin | NASH - Nonalcoholic Steatohepatitis |
| ALT | Metformin | NASH - Nonalcoholic Steatohepatitis |
| AMRN | Icosapent Ethyl 1000 MG [Vascepa] | Lipid Disorder |
| BMEA | BMF-650 | Obesity |
| CMMB | CM-101 | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 100 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 10 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 50 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 150 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Fluvoxamine | Antipsychotic Induced Weight Gain |
| CORT | Olanzapine | Antipsychotic-induced Weight Gain |
| CORT | CORT118335 | Antipsychotic-induced Weight Gain |
| ENTA | EDP-297 | NASH - Nonalcoholic Steatohepatitis With Liver Fib |
| ENTA | Oral Contraceptive | NASH - Nonalcoholic Steatohepatitis |
| ENTA | EDP-305 | NASH - Nonalcoholic Steatohepatitis |
| ENTA | EDP 305 | NASH - Nonalcoholic Steatohepatitis |
| ENTA | intraconazole | NASH - Nonalcoholic Steatohepatitis |
| FATE | ProHema-CB Transplant | Metabolic Disorders |
| IBIO | IBIO-600 | Overweight , Obesity |
| IBIO | IBIO-610 | Obesity & Overweight |
| ICLR | Petrelintide | Obesity & Overweight |
| IMCR | IMC-S118AI | Type 1 Diabetes |
| KLRA | KAI-4729 | Overweight or Obesity |
| LEXX | Arm 4 - Rybelsus medication (semaglutide | Type2diabetes |
| LEXX | Arm 5- Tirzepatide | Type2diabetes |
| LEXX | Arm 2 - DehydraTECH-semaglutide alone | Type2diabetes |
| LEXX | Arm 1 - DehydraTECH-CBD alone | Type2diabetes |
| LEXX | Arm 3 - DehydraTECH-CBD in combination w | Type2diabetes |
| LGND | LGD-6972 Solution | Type 2 Diabetes Mellitus (T2DM) |
| LGND | LGD-6972 Capsules | Type 2 Diabetes Mellitus (T2DM) |
| LGND | LGD-6972 | Type 2 Diabetes Mellitus |
| LLY | LY4057996 IV | Diabetes Mellitus, Type 1 |
| LLY | Degludec IV | Diabetes Mellitus, Type 1 |
| LLY | Pre-study basal insulin SC | Diabetes Mellitus, Type 1 |
| LLY | Degludec SC | Diabetes Mellitus, Type 1 |
Track obesity and metabolic disease catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a obesity and metabolic disease watchlist in minutes.
Start free →